LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Blueprint Medicines Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

127.83 -0.02

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

127.51

Max

128.01

Pagrindiniai rodikliai

By Trading Economics

Pajamos

50M

496K

Pardavimai

3M

149M

Pelnas, tenkantis vienai akcijai

-0.294

Pelno marža

0.332

Darbuotojai

682

EBITDA

-14M

-41M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+1.35% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-07-31

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

2.5B

8.3B

Ankstesnė atidarymo kaina

127.85

Ankstesnė uždarymo kaina

127.83

Naujienos nuotaikos

By Acuity

32%

68%

87 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Blueprint Medicines Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-02 09:17; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2025-06-02 05:31; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2025-06-02 13:50; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2025-06-02 10:50; UTC

Įsigijimai, susijungimai, perėmimai

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2025-06-02 10:05; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2025-06-02 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2025-06-02 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2025-06-02 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2025-06-02 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2025-06-02 05:04; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2025-06-02 05:04; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2025-06-02 05:03; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Blueprint Medicines Corporation

2025-06-02 05:02; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Acquire Blueprint Medicines Corporation

Akcijų palyginimas

Kainos pokytis

Blueprint Medicines Corp Prognozė

Kainos tikslas

By TipRanks

1.35% į viršų

12 mėnesių prognozė

Vidutinis 129.63 USD  1.35%

Aukščiausias 143 USD

Žemiausias 105 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Blueprint Medicines Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

20 ratings

4

Pirkti

16

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

87.66 / 99.25Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

87 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.